keyword
MENU ▼
Read by QxMD icon Read
search

Non small cell lung cancer

keyword
https://www.readbyqxmd.com/read/29676650/the-pluripotency-factor-musashi-2-is-a-novel-target-for-lung-cancer-therapy
#1
Mary R Zhang, Sichuan Xi, Vivek Shukla, Julie A Hong, Haobin Chen, Yin Xiong, R Taylor Ripley, Chuong D Hoang, David S Schrump
Previously we reported that mithramycin represses multiple pathways critical for stem cell signaling and pluripotency in lung cancer cells. This phenomenon coincided with decreased side population fraction and dramatic dose-dependent growth arrest of lung cancer cells in vitro and in vivo. In the present study, microarray, quantitative reverse transcriptase polymerase chain reaction and immunoblot experiments were performed to further examine the effects of mithramycin on stem cell gene expression in lung cancer cells...
April 2018: Annals of the American Thoracic Society
https://www.readbyqxmd.com/read/29676354/diagnostic-and-prognostic-impact-of-mucin-1-6-expression-in-non-small-cell-lung-cancer
#2
William Sterlacci, Michael Fiegl, Lothar Veits, Alexandar Tzankov
Background: The prognostic significance and clinico-pathological characterization of mucin (MUC) expression in non-small cell lung cancer (NSCLC) is controversial and little studied. Aims: This study aims at elucidating this issue on the largest and most detailed cohort so far. Settings and Design: We examined the expression of MUC 1, 2, 4, 5AC and 6 on 371, well documented, surgically resected NSCLC cases. Materials and Methods: Immunohistochemical results were correlated with several of our previously studied, relevant parameters on this cohort including a follow-up period of up to 20 years...
April 2018: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/29675948/pattern-of-care-and-survival-of-anaplastic-lymphoma-kinase-rearranged-non-small-cell-lung-cancer-alk-nsclc-in-an-australian-metropolitan-tertiary-referral-centre-a-retrospective-cohort-analysis
#3
Malinda Itchins, Sarah A Hayes, Anthony J Gill, Wendy Cooper, Rachel O'Connell, Viive M Howell, Stephen J Clarke, Nick Pavlakis
AIM: To report on the pattern of care and survival of anaplastic lymphoma kinase rearranged non-small cell lung cancer (ALK+NSCLC) in a real-world retrospective cohort from an Australian tertiary referral center. METHODS: Individuals with a pathological diagnosis of ALK+NSCLC via immunohistochemistry and fluorescence in situ hybridization and a radiological diagnosis of stage IV disease were eligible. Patients were identified via the Pathology Department specimen database and electronic patient chart review...
April 19, 2018: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29675791/chemotherapy-treatment-is-associated-with-altered-pd-l1-expression-in-lung-cancer-patients
#4
Lívia Rojkó, Lilla Reiniger, Vanda Téglási, Katalin Fábián, Orsolya Pipek, Attila Vágvölgyi, László Agócs, János Fillinger, Zita Kajdácsi, József Tímár, Balázs Döme, Zoltán Szállási, Judit Moldvay
OBJECTIVES: While the predictive value of programmed cell death ligand-1 (PD-L1) protein expression for immune checkpoint inhibitor therapy of lung cancer has been extensively studied, the impact of standard platinum-based chemotherapy on PD-L1 or programmed cell death-1 (PD-1) expression is unknown. The aim of this study was to determine the changes in PD-L1 expression of tumor cells (TC) and immune cells (IC), in PD-1 expression of IC, and in the amount of stromal mononuclear cell infiltration after platinum-based chemotherapy in patients with lung cancer...
April 19, 2018: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29675747/retreatment-with-pembrolizumab-in-advanced-non-small-cell-lung-cancer-patients-previously-treated-with-nivolumab-emerging-reports-of-12-cases
#5
Kohei Fujita, Naohiro Uchida, Osamu Kanai, Misato Okamura, Koichi Nakatani, Tadashi Mio
PURPOSE: After approval of anti-programmed cell death (PD)-1 antibodies, treatment for non-small cell lung cancer (NSCLC) has drastically changed. However, even in patients with favorable effects, therapeutic efficacy does not last long. Recently, retreatment with anti-PD-1 antibody has received attention. The aim of this study was to evaluate the efficacy and safety of retreatment with pembrolizumab in NSCLC patients previously treated with nivolumab. PATIENTS AND METHODS: We retrospectively reviewed NSCLC patients retreated with pembrolizumab who were previously treated with nivolumab...
April 19, 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29675281/coexistent-non-small-cell-carcinoma-and-small-cell-carcinoma-in-a-patient-presenting-with-hyponatremia
#6
Mitchell D Ross, Sreeja Biswas Roy, Pradnya D Patil, Jasmine L Huang, Nitika Thawani, Ralph Drosten, Tanmay S Panchabhai
Despite recent advances in screening methods, lung cancer remains the leading cause of cancer-related deaths worldwide. By the time lung cancer becomes symptomatic and patients seek treatment, it is often too advanced for curative measures. Low-dose computed tomography (CT) screening has been shown to reduce mortality in patients at high risk of lung cancer. We present a 66-year-old man with a 50-pack-year smoking history who had a right upper lobe (RUL) pulmonary nodule and left lower lobe (LLL) consolidation on a screening CT...
2018: Case Reports in Pulmonology
https://www.readbyqxmd.com/read/29675110/evaluation-of-detection-methods-and-values-of-circulating-vascular-endothelial-growth-factor-in-lung-cancer
#7
REVIEW
Sumin Guo, Michael G Martin, Cheng Tian, Jinglin Cui, Lishi Wang, Shucai Wu, Weikuan Gu
Lung cancer is the deadliest cancer in the world. Angiogenesis plays a crucial role of the incidence, progression, and metastasis in lung cancer. Angiogenesis inhibitors are used to treat non-small cell lung cancer (NSCLC) patients, and the molecular biomarkers are also being assessed to predict treatment response/therapeutic response and patients' prognosis. Vascular endothelial growth factor (VEGF) is a signal protein produced by cells that stimulates angiogenesis. Due to its predictive values of prognosis on NSCLC, a large number of methods have been developed and evaluated to detect VEGF levels in a variety of studies...
2018: Journal of Cancer
https://www.readbyqxmd.com/read/29675106/overexpression-of-klotho-inhibits-helf-fibroblasts-sasp-related-protumoral-effects-on-non-small-cell-lung-cancer-cells
#8
Bo Chen, Yan Liang, Liben Chen, Yunyan Wei, Yue Li, Weihong Zhao, Jianqing Wu
Lung cancer (LC) is the most common cause of death from cancer worldwide, and it is also a closely aging-related disease. Klotho, a new anti-aging gene, has been proven to play a critical role in regulating aging and the development of age-related diseases including LC. However, whether Klotho is a key link between aging and LC is still unknown. Here we report that Klotho can indirectly inhibit LC growth and development through regulating senescence-associated secretory phenotype (SASP). We found that senescent lung fibroblasts (SLF) can promote production of IL-6 and IL-8, which can be effectively inhibited by overexpressing Klotho...
2018: Journal of Cancer
https://www.readbyqxmd.com/read/29675101/a-network-meta-analysis-comparing-the-efficacy-and-safety-of-anti-pd-1-with-anti-pd-l1-in-non-small-cell-lung-cancer
#9
Wei You, Mei Liu, Ji-Dong Miao, Yu-Qian Liao, Yi-Bing Song, Dian-Kun Cai, Yang Gao, Hao Peng
Background : This network meta-analysis aimed at comparing anti-programmed death 1 (anti-PD-1) with anti-programmed death ligand 1(anti-PD-L1) immunotherapy in patients with metastatic, previously treated non-small cell lung cancer (NSCLC) who failed first-line treatment. Methods : We searched electronic databases to identify all eligible clinical trials. End-points included overall survival (OS), progression-free survival (PFS) and objective response. Hazard ratios (HRs) or odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were extracted...
2018: Journal of Cancer
https://www.readbyqxmd.com/read/29675061/comorbidities-with-non-small-cell-lung-cancer-is-there-an-interdisciplinary-consensus-needed-to-qualify-patients-for-surgical-treatment
#10
Marta Lembicz, Piotr Gabryel, Beata Brajer-Luftmann, Wojciech Dyszkiewicz, Halina Batura-Gabryel
INTRODUCTION: Radical surgical treatment is the preferred action for patients with early-stage non-small cell lung cancer (NSCLC). Qualification for surgical treatment should consider a risk associated with the effect of comorbidities on the general condition of the patient. The aim of this article was an attempt to identify the risk factors for postoperative complications in patients treated for NSCLC, with a special focus on the coexisting diseases. METHODS: A total of 400 patients with NSCLC were included in this retrospective study...
April 2018: Annals of Thoracic Medicine
https://www.readbyqxmd.com/read/29675057/causes-of-death-in-long-term-survivors-of-non-small-cell-lung-cancer-a-regional-surveillance-epidemiology-and-end-results-study
#11
Amaraja A Kanitkar, Ann G Schwartz, Julie George, Ayman O Soubani
INTRODUCTION: Survival from lung cancer is improving. There are limited data on the causes of death in 5-year survivors of lung cancer. The aim of this study is to explore the causes of death in long-term survivors of non-small cell lung cancer (NSCLC) and describe the odds of dying from causes other than lung cancer in this patient population. METHODS: An analysis of 5-year survivors of newly diagnosed NSCLC from 1996 to 2007, in Metropolitan Detroit included in Surveillance, Epidemiology, and End Results program, was done...
April 2018: Annals of Thoracic Medicine
https://www.readbyqxmd.com/read/29674424/utilizing-radiolabeled-3-deoxy-3-18-f-fluorothymidine-with-positron-emission-tomography-to-monitor-the-effect-of-dexamethasone-on-non-small-cell-lung-cancer
#12
Christopher McHugh, Monica R Thipparthi, Jawana M Lawhorn-Crews, Lisa Polin, Shirish Gadgeel, Janice Akoury, Thomas J Mangner, Kirk A Douglas, Jing Li, Manohar Ratnam, Anthony F Shields
Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality in the United States and pemetrexed-based therapies are regularly used to treat non-squamous NSCLC. Despite widespread use, pemetrexed has a modest effect on progression-free survival, with varying efficacy between individuals. Recent work has indicated that dexamethasone, given to prevent pemetrexed toxicity, is able to protect a subset of NSCLC cells from pemetrexed cytotoxicity by temporarily suppressing of the S-phase of the cell cycle...
April 19, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29674275/cdk16-overexpressed-in-non-small-cell-lung-cancer-and-regulates-cancer-cell-growth-and-apoptosis-via-a-p27-dependent-mechanism
#13
Hongtao Wang, Hongli Liu, Shengping Min, Yuanbing Shen, Wei Li, Yuqing Chen, Xiaojing Wang
Cyclin-dependent kinase 16 (CDK16, PCTAIRE1) expression is upregulated in a wide variety of human malignancies. However, the function(s) of CDK16 in non-small cell lung cancer (NSCLC) remain unknown. Therefore, here we investigated the role of CDK16 in NSCLC. From 43 NSCLC tumors and matching healthy control lung tissues, immunohistochemistry revealed significantly greater CDK16 and phospho-p27Ser10 staining levels in NSCLC samples relative to healthy controls. The NSCLC cell line EKVX was transfected with a control siRNA, a CDK16-siRNA, or CDK16-siRNA + p27-siRNA...
April 16, 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29674274/a-novel-synthetic-curcumin-derivative-mhmm-41-induces-ros-mediated-apoptosis-and-migration-blocking-of-human-lung-cancer-cells-a549
#14
Guang-Zhou Zhou, A-Fang Li, Yan-He Sun, Gang-Chun Sun
Many curcumin derivatives were produced and characterized to improve the physiochemical instability and low solubility of curcumin. Here, MHMM-41 (a novel curcumin derivative) was used to treat non-small lung cancer cells of human (known as A549) and to identify its anti-proliferative activities. Our results suggested that MHMM-41 display no significant cytotoxicity toward normal human lung fibroblast 2BS cells and mouse embryonal fibroblast 3T3 cells. It also had better anti-proliferative activity than curcumin in A549 cells...
April 16, 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29674272/copb2-promotes-cell-proliferation-and-tumorigenesis-through-up-regulating-yap1-expression-in-lung-adenocarcinoma-cells
#15
Xiaolin Pu, Jun Wang, Wei Li, Weifei Fan, Lin Wang, Yuan Mao, Shu Yang, Suyao Liu, Juqing Xu, Zhigang Lv, Lin Xu, Yongqian Shu
Lung adenocarcinoma is the most common subtype of non-small cell lung cancer and responsible for more than 500,000 deaths per year worldwide. In this study, we aimed to explore the effects of COPB2 in the progression of lung adenocarcinoma and its underlying mechanism. The mRNA and protein levels of COPB2 in tumor tissues and cell lines were determined by qRT-PCR and western blotting analysis. siRNAs and over-expressed vector targeting COPB2 were used to down-regulate and up-regulate COPB2 expression in lung adenocarcinoma cell lines H1975...
April 16, 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29673274/drug-wastage-and-costs-to-the-healthcare-system-in-the-care-of-patients-with-non-small-cell-lung-cancer-in-the-united-states
#16
Lisa M Hess, Zhanglin Lin Cui, Xiaohong Ivy Li, Ana B Oton, Scott Shortenhaus, Ian A Watson
BACKGROUND: Lung cancer is one of the most prevalent cancers in the United States. This study was designed to evaluate the actual drug wastage and cost to the healthcare system using patient-level retrospective observational electronic medical record (EMR) data from a cohort of lung cancer patients in the United States (US). METHODS: Data from the Flatiron Health advanced non-small cell lung cancer (NSCLC) cohort was used for this study. Drug administered amount (in mg) was used to determine an optimal set of available vial sizes to minimize waste...
April 19, 2018: Journal of Medical Economics
https://www.readbyqxmd.com/read/29673125/major-pathologic-response-and-rad51-predict-survival-in-lung-cancer-patients-receiving-neoadjuvant-chemotherapy
#17
Apar Pataer, Ruping Shao, Arlene M Correa, Carmen Behrens, Jack A Roth, Ara A Vaporciyan, Ignacio I Wistuba, Stephen G Swisher
In a previous study, we determined that major pathologic response (MPR) as indicated by the percentage of residual viable tumor cells predicted overall survival (OS) in patients with non-small-cell lung cancer (NSCLC) who received neoadjuvant chemotherapy. In this study, we assessed whether two genes and five protein biomarkers could predict MPR and OS in 98 patients with NSCLC receiving neoadjuvant chemotherapy. We collected formalin-fixed, paraffin-embedded specimens of resected NSCLC tumors from 98 patients treated with neoadjuvant chemotherapy...
April 19, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29673089/non-small-cell-lung-cancer-harboring-a-rare-egfr-l747p-mutation-showing-intrinsic-resistance-to-both-gefitinib-and-osimertinib-azd9291-a-case-report
#18
Jing Huang, Yiyin Wang, Yachao Zhai, Jin Wang
The most common EGFR mutations in non-small cell lung cancer are exon 19 deletions and exon 21 point mutations, which are both sensitive to EGFR-tyrosine kinase inhibitors. However, rare EGFR mutations do exist and how these mutations respond to tyrosine kinase inhibitors is not well understood. A Chinese woman diagnosed with stage IV lung adenocarcinoma harbored a rare EGFR L747P (2239-2240 TT > CC) mutation, and treatment with gefitinib and osimertinib failed to achieve the desired effect. Herein, possible correlations between gene analysis and the outcomes of subsequent treatment are discussed...
April 19, 2018: Thoracic Cancer
https://www.readbyqxmd.com/read/29672849/baseline-neutrophilia-derived-neutrophil-to-lymphocyte-ratio-dnlr-platelet-to-lymphocyte-ratio-plr-and-outcome-in-non-small-cell-lung-cancer-nsclc-treated-with-nivolumab-or-docetaxel
#19
Alessandro Russo, Tindara Franchina, Giuseppina R R Ricciardi, Alessandra Battaglia, Antonino Scimone, Rosa Berenato, Antonio Giordano, Vincenzo Adamo
Nivolumab is a novel therapeutic option in NSCLC, associated with a significant survival gain compared with Docetaxel. However, predictive biomarkers are lacking. The presence of systemic inflammation has been correlated with poor outcome in many cancer types. We aimed to evaluate whether there is a correlation between some indicators of inflammation and response to Nivolumab or Docetaxel in pre-treated NSCLCs. Data of 62 patients receiving Nivolumab or Docetaxel were analyzed. Baseline neutrophilia and thrombocytosis were not associated with response...
April 19, 2018: Journal of Cellular Physiology
https://www.readbyqxmd.com/read/29671943/epithelial-to-mesenchymal-transition-in-the-context-of-epidermal-growth-factor-receptor-inhibition-in-non-small-cell-lung-cancer
#20
Giuseppe Bronte, Sara Bravaccini, Enrico Bronte, Marco Angelo Burgio, Christian Rolfo, Angelo Delmonte, Lucio Crinò
The identification of oncogenic driver mutations in non-small-cell lung cancer (NSCLC) has led to the development of targeted drugs. Tyrosine kinase inhibitors (TKIs) directed against the epidermal growth factor receptor (EGFR) target lung tumours bearing EGFR-activating mutations. This new therapeutic strategy has greatly improved tumour response rates. However, drug resistance invariably occurs during TKI-based treatment. Epithelial-to-mesenchymal transition (EMT) is one of the resistance mechanisms identified in EGFR-mutated NSCLC treated with TKIs...
April 19, 2018: Biological Reviews of the Cambridge Philosophical Society
keyword
keyword
8878
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"